Letram Drug Interactions

Data indicate that Levetiracetam did not influence the serum concentrations of existing antiepileptic medicinal products (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these antiepileptic medicinal products did not influence the pharmacokinetics of Levetiracetam.
The clearance of Levetiracetam was 22 % higher in children taking enzyme-inducing AEDs compared to children who did not take enzyme-inducing AEDs. Dose adjustments are not recommended. Levetiracetam had no effect on plasma concentrations of carbamazepine, valproate, topiramate, or lamotrigine.
Probenecid (500 mg four times daily) a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite but not of Levetiracetam. Nevertheless, the concentration of this metabolite remains low. It is expected that other medicinal products excreted by active tubular secretion could also reduce the renal clearance of the metabolite. The effect of Levetiracetam on probenecid was not studied and the effect of Levetiracetam on other actively secreted medicinal products, e.g. NSAIDs, sulphonamides and methotrexate is unknown.
Levetiracetam 1000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinylestradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified. Levetiracetam 2000 mg daily did not influence the pharmacokinetics of digoxin and warfarin; prothrombin times were not modified. Co-administration with digoxin, oral contraceptives and warfarin did not influence the pharmacokinetics of Levetiracetam.
No data on the influence of antacids on the absorption of Levetiracetam are available. The extent of absorption of Levetiracetam was not altered by food, but the rate of absorption was slightly reduced.
No data on the interaction of Levetiracetam with alcohol are available.